Cell based therapy in Parkinsonism

Translational Neurodegeneration

Volumn 2, Issue 1, 2013, Pages

  de Munter, Johannes P J M ^a,b   Lee, Chongsik ^c   Wolters, Erik C ^a,d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Amarna Stem Cells Group   (Netherlands)

^c Asan Medical Center   (South Korea)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adult stem cells; BDNF; Expanded MSC; GDNF; Multiple system atrophy; Parkinson's disease; Preclinical

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; DOPAMINE; ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROTROPHIN 3; PLACEBO; STROMAL CELL DERIVED FACTOR 1ALPHA; TYROSINE 3 MONOOXYGENASE;

ADULT STEM CELL; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL TRANSDIFFERENTIATION; DOPAMINE RELEASE; ECTODERMAL STEM CELL; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; IMMUNE RESPONSE; MESENCHYMAL STEM CELL; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; RISK REDUCTION; SHY DRAGER SYNDROME; STEM CELL TRANSPLANTATION; STRIATE CORTEX;

EID: 84883602441     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-2-13     Document Type: Review

References (74)

1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011, 26(Suppl 1):S1-S58.
2. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68(5):384-386. 10.1212/01.wnl.0000247740.47667.03, 17082464.
3. Diem-Zangerl A, Seppi K, Oberaigner W, Poewe W. Mortality in Parkinson's disease, a 20-year follow-up study. Mov Disord 2010, 25(5):661-662. 10.1002/mds.22934, 20201025.
4. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 2008, 70(16 Pt 2):1423-1430.
5. Wolters EC, Van Laar T, Berendse HW. Parkinsonism and related disorders 2010, 143-158. VU University Press, Third Edition.
6. Marsden CD. Movement Disorders. Oxford Textbook of Medicine. 1996, 3:3998-4022.
7. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011, 26(Suppl 3):S2-S41.
8. Fillmore HL, Holloway KL, Gillies GT. Cell replacement efforts to repair neuronal injury: a potential paradigm for the treatment of Parkinson's disease. NeuroRehabilitation 2005, 20(3):233-242.
9. Hall VJ, Li JY, Brundin P. Restorative cell therapy for Parkinson's disease: a quest for the perfect cell. Semin Cell Dev Biol 2007, 18(6):859-869. 10.1016/j.semcdb.2007.09.004, 17962052.
10. Laguna Goya R, Tyers P, Barker RA. The search for a curative cell therapy in Parkinson's disease. J Neurol Sci 2008, 265(1-2):32-42.
11. Meyer AK, Maisel M, Hermann A, Stirl K, Storch A. Restorative approaches in Parkinson's Disease: which cell type wins the race?. J Neurol Sci 2010, 289(1-2):93-103.
12. Parish CL, Arenas E. Stem-cell-based strategies for the treatment of Parkinson's disease. Neurodegener Dis 2007, 4(4):339-347. 10.1159/000101892, 17627139.
13. Fujikawa T, Oh SH, Pi L, Hatch HM, Shupe T, Petersen BE. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol 2005, 166(6):1781-1791. 10.1016/S0002-9440(10)62488-1, 1602425, 15920163.
14. Hentze H, Graichen R, Colman A. Cell therapy and the safety of embryonic stem cell-derived grafts. Trends Biotechnol 2007, 25(1):24-32. 10.1016/j.tibtech.2006.10.010, 17084475.
15. Lee AS, Tang C, Cao F, Xie X, van der Bogt K, Hwang A. Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle 2009, 8(16):2608-2612. 10.4161/cc.8.16.9353, 2866168, 19597339.
16. Ben-David U, Benvenisty N, Mayshar Y. Genetic instability in human induced pluripotent stem cells: classification of causes and possible safeguards. Cell Cycle 2010, 9(23):4603-4604. 10.4161/cc.9.23.14094, 21099357.
17. Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D. Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases. Isr Med Assoc J 2009, 11(4):201-204.
18. de Munter JP, Wolters EC. Autologous stem cells in neurology: is there a future?. J Neural Transm 2013, 120(1):65-73. 10.1007/s00702-012-0913-9, 23180301.
19. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105(4):1815-1822. 10.1182/blood-2004-04-1559, 15494428.
20. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106(5):1755-1761. 10.1182/blood-2005-04-1496, 15905186.
21. Barzilay R, Kan I, Ben-Zur T, Bulvik S, Melamed E, Offen D. Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells Dev 2008, 17(3):547-554. 10.1089/scd.2007.0172, 18513164.
22. Tropel P, Platet N, Platel JC, Noel D, Albrieux M, Benabid AL. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006, 24(12):2868-2876. 10.1634/stemcells.2005-0636, 16902198.
23. Ye Y, Zeng YM, Wan MR, Lu XF. Induction of human bone marrow mesenchymal stem cells differentiation into neural-like cells using cerebrospinal fluid. Cell Biochem Biophys 2011, 59(3):179-184. 10.1007/s12013-010-9130-z, 21210249.
24. Zeng R, Wang LW, Hu ZB, Guo WT, Wei JS, Lin H. Differentiation of Human Bone Marrow Mesenchymal Stem Cells into Neuron-like Cells in Vitro. Spine 2011, 36(13):997-1005. 10.1097/BRS.0b013e3181eab764, 21270716.
25. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008, 103(11):1204-1219. 10.1161/CIRCRESAHA.108.176826, 2667788, 19028920.
26. Xu YX, Chen L, Wang R, Hou WK, Lin P, Sun L. Mesenchymal stem cell therapy for diabetes through paracrine mechanisms. Med Hypotheses 2008, 71(3):390-393. 10.1016/j.mehy.2008.03.046, 18538944.
27. Jager M, Hernigou P, Zilkens C, Herten M, Li X, Fischer J. Cell therapy in bone healing disorders. Orthopedic reviews 2010, 2(2):79-87.
28. Croft AP, Przyborski SA. Mesenchymal stem cells expressing neural antigens instruct a neurogenic cell fate on neural stem cells. Exp Neurol 2009, 216(2):329-341. 10.1016/j.expneurol.2008.12.010, 19159625.
29. Tondreau T, Lagneaux L, Dejeneffe M, Massy M, Mortier C, Delforge A. Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation 2004, 72(7):319-326. 10.1111/j.1432-0436.2004.07207003.x, 15554943.
30. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 2009, 3:63-70. 10.1016/j.scr.2009.02.006, 19411199.
31. Du Y, Li X, Yang D, Zhang X, Chen S, Huang K. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Exp Biol Med 2008, 233(7):881-890.
32. Wang F, Yasuhara T, Shingo T, Kameda M, Tajiri N, Yuan WJ. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci 2010, 11(52):1-9.
33. Geeraerts T, Deiva K, M'Sika I, Salim H, Hery C, Tardieu M. Effects of SDF-1alpha and gp120IIIB on apoptotic pathways in SK-N-SH neuroblastoma cells. Neurosci Lett 2006, 399(1-2):115-120.
34. Shyu WC, Lin SZ, Yen PS, Su CY, Chen DC, Wang HJ. Stromal cell-derived factor-1 alpha promotes neuroprotection, angiogenesis, and mobilization/homing of bone marrow-derived cells in stroke rats. J Pharmacol Exp Ther 2008, 324(2):834-849.
35. Zhu B, Xu D, Deng X, Chen Q, Huang Y, Peng H. CXCL12 enhances human neural progenitor cell survival through a CXCR7- and CXCR4-mediated endocytotic signaling pathway. Stem Cells 2012, 30(11):2571-2583. 10.1002/stem.1239, 22987307.
36. Delcroix GJ, Curtis KM, Schiller PC, Montero-Menei CN. EGF and bFGF pre-treatment enhances neural specification and the response to neuronal commitment of MIAMI cells. Differentiation 2010, 80(4-5):213-227.
37. Delcroix GJ, Garbayo E, Sindji L, Thomas O, Vanpouille-Box C, Schiller PC. The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats. Biomaterials 2011, 32(6):1560-1573. 10.1016/j.biomaterials.2010.10.041, 21074844.
38. Blits B, Kitay BM, Farahvar A, Caperton CV, Dietrich WD, Bunge MB. Lentiviral vector-mediated transduction of neural progenitor cells before implantation into injured spinal cord and brain to detect their migration, deliver neurotrophic factors and repair tissue. Restor Neurol Neurosci 2005, 23(5-6):313-324.
39. Bjorklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000, 886(1-2):82-98.
40. Chen L, He DM, Zhang Y. The differentiation of human placenta-derived mesenchymal stem cells into dopaminergic cells in vitro. Cell Mol Biol Lett 2009, 14(3):528-536. 10.2478/s11658-009-0015-3, 19412574.
41. Kim YJ, Park HJ, Lee G, Bang OY, Ahn YH, Joe E. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. Glia 2009, 57(1):13-23. 10.1002/glia.20731, 18661552.
42. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 2009, 18(5):683-692. 10.1089/scd.2008.0253, 3190292, 19099374.
43. Jackson JS, Golding JP, Chapon C, Jones WA, Bhakoo KK. Homing of stem cells to sites of inflammatory brain injury after intracerebral and intravenous administration: a longitudinal imaging study. Stem Cell Res Ther 2010, 1(2):1-12.
44. Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. Curr Neuropharmacol 2008, 6(3):179-192. 10.2174/157015908785777210, 2687937, 19506719.
45. Zhang C, Zhou C, Teng JJ, Zhao RL, Song YQ. Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in a transgenic mouse model of amyotrophic lateral sclerosis. Cytotherapy 2009, 11(3):299-306. 10.1080/14653240902806986, 19333801.
46. Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 2011, 164(4):1357-1391. 10.1111/j.1476-5381.2011.01426.x, 3229766, 21486284.
47. Garea-Rodriguez E, Schlumbohm C, Czeh B, Konig J, Helms G, Heckmann C. Visualizing dopamine transporter integrity with iodine-123-FP-CIT SPECT in combination with high resolution MRI in the brain of the common marmoset monkey. J Neurosci Methods 2012, 210(2):195-201. 10.1016/j.jneumeth.2012.07.009, 22827895.
48. Guo J, Zeng Y, Liang Y, Wang L, Su H, Wu W. Cyclosporine affects the proliferation and differentiation of neural stem cells in culture. Neuroreport 2007, 18(9):863-868. 10.1097/WNR.0b013e32811d6d36, 17515791.
49. Ibarra A, Correa D, Willms K, Merchant MT, Guizar-Sahagun G, Grijalva I. Effects of cyclosporin-A on immune response, tissue protection and motor function of rats subjected to spinal cord injury. Brain Res 2003, 979(1-2):165-178.
50. Palladini G, Caronti B, Pozzessere G, Teichner A, Buttarelli FR, Morselli E. Treatment with cyclosporine A promotes axonal regeneration in rats submitted to transverse section of the spinal cord-II-Recovery of function. J Hirnforsch 1996, 37(1):145-153.
51. Bouchez G, Sensebe L, Vourc'h P, Garreau L, Bodard S, Rico A. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem Int 2008, 52(7):1332-1342. 10.1016/j.neuint.2008.02.003, 18372079.
52. Park HJ, Lee PH, Bang OY, Lee G, Ahn YH. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J Neurochem 2008, 107(1):141-151. 10.1111/j.1471-4159.2008.05589.x, 18665911.
53. Danielyan L, Schafer R, von Ameln-Mayerhofer A, Bernhard F, Verleysdonk S, Buadze M. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 2011, 14(1):3-16. 10.1089/rej.2010.1130, 21291297.
54. Chao YX, He BP, Tay SS. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease. J Neuroimmunol 2009, 216(1-2):39-50.
55. Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev 2009, 18(8):1179-1190. 10.1089/scd.2008.0411, 19243240.
56. Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy 2008, 10(4):340-352. 10.1080/14653240802021330, 18574767.
57. Cova L, Armentero MT, Zennaro E, Calzarossa C, Bossolasco P, Busca G. Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. Brain Res 2010, 1311:12-27.
58. Blandini F, Cova L, Armentero MT, Zennaro E, Levandis G, Bossolasco P. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 2010, 19(2):203-217. 10.3727/096368909X479839, 19906332.
59. Zhu Q, Ma J, Yu L, Yuan C. Grafted neural stem cells migrate to substantia nigra and improve behavior in Parkinsonian rats. Neurosci Lett 2009, 462(3):213-218. 10.1016/j.neulet.2009.07.008, 19596403.
60. Bjugstad KB, Teng YD, Redmond DE, Elsworth JD, Roth RH, Cornelius SK. Human neural stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson's disease. Exp Neurol 2008, 211(2):362-369. 10.1016/j.expneurol.2008.01.025, 2483423, 18394605.
61. Ramos-Moreno T, Castillo CG, Martinez-Serrano A. Long term behavioral effects of functional dopaminergic neurons generated from human neural stem cells in the rat 6-OH-DA Parkinson's disease model. Effects of the forced expression of BCL-X(L). Behav Brain Res 2012, 232(1):225-232. 10.1016/j.bbr.2012.04.020, 22537773.
62. Park HJ, Bang G, Lee BR, Kim HO, Lee PH. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism. Cell Transplant 2011, 20(6):827-835. 10.3727/096368910X540630, 21054946.
63. Lee PH, Kim JW, Bang OY, Ahn YH, Joo IS, Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2008, 83(5):723-730. 10.1038/sj.clpt.6100386, 17898702.
64. Venkataramana NK, Kumar SK, Balaraju S, Radhakrishnan RC, Bansal A, Dixit A. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Translational research : the journal of laboratory and clinical medicine 2010, 155(2):62-70.
65. Venkataramana NK, Pal R, Rao SA, Naik AL, Jan M, Nair R. Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson's disease: a pilot clinical study. Stem Cells Int. 2012, ID931902:1-12.
66. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008, 102(11):1319-1330. 10.1161/CIRCRESAHA.108.175943, 2728476, 18535269.
67. Li TS, Kubo M, Ueda K, Murakami M, Mikamo A, Hamano K. Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure. J Thorac Cardiovasc Surg 2010, 139(2):459-465. 10.1016/j.jtcvs.2009.07.053, 19748631.
68. Koh SH, Baik W, Noh MY, Cho GW, Kim HY, Kim KS. The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate. Exp Neurol 2012, 233(1):472-480. 10.1016/j.expneurol.2011.11.021, 22119626.
69. Zhang Z, Wang X, Wang S. Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson's disease. In Vitro Cell Dev Biol Anim 2008, 44(5-6):169-177.
70. Somoza R, Juri C, Baes M, Wyneken U, Rubio FJ. Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease. Biol Blood Marrow Transplant 2010, 16(11):1530-1540. 10.1016/j.bbmt.2010.06.006, 20542127.
71. Ourednik J, Ourednik V, Lynch WP, Schachner M, Snyder EY. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol 2002, 20(11):1103-1110. 10.1038/nbt750, 12379867.
72. Chen X, Liu W, Guoyuan Y, Liu Z, Smith S, Calne DB. Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease. Parkinsonism Relat Disord 2003, 10(1):1-7. 10.1016/S1353-8020(03)00097-X, 14499199.
73. McCluskey L, Campbell S, Anthony D, Allan SM. Inflammatory responses in the rat brain in response to different methods of intra-cerebral administration. J Neuroimmunol 2008, 194(1-2):27-33.
74. Perry VH, Bell MD, Brown HC, Matyszak MK. Inflammation in the nervous system. Curr Opin Neurobiol 1995, 5(5):636-641. 10.1016/0959-4388(95)80069-7, 8580715.